Postdoc researcher in Genetics and Molecular Biology. Interested in genomics,transcriptomics, integration and brain. Cyclist in my free time and cat lover!
Most psychiatric GWAS are Eurocentric, limiting relevance across ancestries. Latin America’s genetic and environmental architecture offers a chance to advance global discovery. See the recent review by the Latin American Genomics Consortium (LAGC)🌎📷🧬
https://t.co/ThenyQN0QC
From Methods working group of the @LAGCPsychGene : A great and interesting work about Local Ancestry Inference (LAI) that is a promising strategy to leverage this admixture across the genetics studies. Congrats @mauer_jh @egatkinson@MarcosSantoro9 ! Check it out
Hello, everyone! Over the next two weeks, I'd like to invite you to learn what is being done to understand psychiatric disorders in Latin American populations. If you're interested, join us! @LAGCPsychGene#latinamerican#genetics
I am delighted to announce that @mauer_jh’s first paper with me is up on biorxiv! Their work thoroughly evaluates features affecting local ancestry inference across many (I mean many) simulated demographic and data models to advise on best practices.
Were you planning on attending the Tractor GWAS Bootcamp? You still can. The Bootcamp has been rescheduled for September 20th.
We hope to see you there!
Very exciting to have our newest PGC-PTSD freeze out! Growing diversity and sample sizes are still affording exponential increases in identifying loci influencing PTSD risk. Check out Joni’s wonderful tweetorial for more.
Today is #PurpleDay - a time to raise awareness about epilepsy. So let's spread the word that #epilepsy is a chronic noncommunicable brain disorder that affects around 50 million people of all ages worldwide. https://t.co/zghUKRp94x @yesILAE
For some of us writing doesn’t come natural. Writing in a different language that is not your native language is even harder. Here are some tips that may help you
https://t.co/UwskdN3RP8
Pleased to share our international collaborative effort on "SCN1A Prediction Model" using clinical and genetic biomarkers to predict Dravet syndrome versus other GEFS+ phenotypes in over 1000 patients.
https://t.co/4wxxPdIzz3
Thanks to all collaborators! @LalDennis, @EdoPerezP
Publication alert! Feng et al. Brain Commun.
We show that poorer baseline language ability, more severe epilepsy severity and worse SCN1A genetic score predict worse outcome in DS at 10-year F/U. Identified biomarkers emphasise importance of early focused therapies in DS.
The economy!
Pharmacogenomic testing is a big long-term cost-saver in depression treatment, according to this set of comprehensive analyses - see https://t.co/FW8f2JWjym
Take home:
"Pharmacogenomic testing ... was predicted to save the health system $956 million ($4926 per patient) ... These savings were mainly driven by slowing or avoiding the transition to refractory (treatment-resistant) depression ... Sensitivity analyses estimated that costs of pharmacogenomic testing would be offset within about 2 years of implementation.